Jazz Pharmaceuticals JAZZ Gain (Loss), Foreign Currency Transaction, before Tax
Gain (Loss), Foreign Currency Transaction, before Tax at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's gain (loss), foreign currency transaction, before tax?
- Jazz Pharmaceuticals (JAZZ) reported gain (loss), foreign currency transaction, before tax of $2.5M in Q1 2026.
- How has Jazz Pharmaceuticals's gain (loss), foreign currency transaction, before tax changed year-over-year?
- Jazz Pharmaceuticals's gain (loss), foreign currency transaction, before tax increased by 1350.0% year-over-year, from -$200K to $2.5M.
- What is the long-term trend for Jazz Pharmaceuticals's gain (loss), foreign currency transaction, before tax?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's gain (loss), foreign currency transaction, before tax has grown at a -12.5% compound annual growth rate (CAGR), from -$4.35M to -$2.56M.